650
Participants
Start Date
January 31, 2008
Primary Completion Date
April 30, 2012
Study Completion Date
August 31, 2012
Radiotherapy
4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks
Radiotherapy
8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks
Radiotherapy
8 Gy in a single fraction; retreatments \> 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
Radiotherapy
12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments \> 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
Institute of Radiotherapy and Oncology, Skopje
Institute of Oncology and Radiology, Belgrade
Instituto Nacional de Cancerología (INCAN), Mexico City
Centre Pierre et Marie Curie, Centre hospitalier universitaire Mustapha (CHU), Algiers
Irmandade de Santa Casa de Misericordia de Porto Alegre, Porto Alegre
Misr Oncology Center (MOC), Cairo
Tata Memorial Hospital, Mumbai
Institute of Oncology, University of Vilinius, Vilnius
Hospital Clinic Universidad de Barcelona, Barcelona
Hospital Son Dureta, Palma de Mallorca
Institut national de cancer Salah Azaiz, Tunis
Mount Vernon Cancer Centre, Northwood
Lead Sponsor
International Atomic Energy Agency
OTHER_GOV